Last reviewed · How we verify
NCT05525884
Mechanism of Serum PRL in the Development of MAFLD
trial testing non-invasive method, Fibroscan in Type2 Diabetes in 1,000 participants. Status unknown.
1 January 2024
Quick facts
| Lead sponsor | Shen Qu |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 January 2017 |
| Primary completion | 1 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- non-invasive method, Fibroscan
Conditions studied
- Type2 Diabetes — all drugs for Type2 Diabetes →
- Fatty Liver, Nonalcoholic — all drugs for Fatty Liver, Nonalcoholic →
- Liver Fibrosis — all drugs for Liver Fibrosis →
Sponsor
Shen Qu
Who can join
Adults 18 to 65, any sex, with Type2 Diabetes or Fatty Liver, Nonalcoholic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently. However, the relationship between serum PRL and MAFLD among diabetic patients is unclear. The investigators aimed to explore the association between serum PRL and the risk of MAFLD in patients with type 2 diabetes (T2DM).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05525884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2 Diabetes
Currently open trials in the same condition.
- NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
- NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
- NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
- NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
- NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting
Other Shen Qu trials
Trials by the same sponsor.
- NCT05529563 — The Effect of Laparoscopic Sleeve Gastrectomy on Insulin Secretion Pattern in Morbidly Obese Patients With Acanthosis Ni · unknown
- NCT05528393 — Prolactin and FGF21 in Gestational Diabetes Mellitus · unknown
- NCT04573998 — Study on the Mechanism of lcn2 in Obesity · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05525884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shen Qu
- Last refreshed: 2 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing